Abstract:Background: Gliomas comprise about 80 per cent of all malignant brain tumours. Current gliomas staging alone cannot adequately predict prognosis between Glioblastoma multiforme (GBM) and low-grade gliomas (LGG). This study aims to explore effective diagnostic and prognostic biomarkers for gliomas. Methods: We performed consensus clustering to m6A RNA methylation regulators in TCGA-GBM/LGG datasets. The tumour-infiltrating immune cells of The Cancer Genome Atlas (TCGA) gliomas cohort was analyzed by single-sample gene set enrichment analysis (ssGSEA). Four hub gene were identified via weighted gene co-expression network analysis (WGCNA) and least absolute shrinkage, and selection operator (LASSO). The diagnostic and prognostic value were validated by risk score analysis, Kaplan-Meier and ROC. Finding: We identified two glioma subgroups (cluster 1/2) by applying consensus clustering to m6A RNA methylation regulators in 665 gliomas (TCGA-GBM and TCGA-LGG). The cluster 1 subgroup was associated with a poorer prognosis and a higher WHO classification than the cluster 2 subgroup. We performed chi-square test between m6A cluster subgroup and immune infiltration subgroup, the results indicated that the characteristics of the tumor-associated immune infiltration are significantly enriched in the cluster 1 subgroup. These findings suggest that m6A RNA methylation regulators are related to immune infiltration. In order to explore potential hub genes, we performed WGCNA between high/low immune infiltration and m6A cluster 1/2 groups. LASSO was utilized for the hub genes, and four immune and m6A related genes TAGLN2, PDPN, TIMP1, EMP3 were identified as biomarkers for glioma prognosis. Moreover, the 4-gene signature achieved AUC values of 0.80, 0.79, 0.67 and 0.72 in TCGA, Rembrandt, GSE16011 and Chinese Glioma Genome Atlas (CGGA), respectively. Interpretation: These findings provide new insight into gliomas prognosis and identify four genes (TAGLN2, PDPN, TIMP1 and EMP3) as candidate biomarkers for diagnosis and prognosis of glioma. Funding Statement: This work was supported by National Natural Science Foundation of China (no.81701359), Natural science foundation of Shanghai (18ZR1430400), and the Cross Research Fund of Medicine and Engineering of Shanghai Jiaotong University (No. YG2016QN32, YG2019QNA67). Declaration of Interests: The authors have declared that no conflict of interest exists. Ethics Approval Statement: Not required.

Gene Biomarker Prediction in Glioma by Integrating scRNA-seq Data and the Gene Regulatory Network

Transcriptomic Profiling Identifies a Nucleotide Metabolism-Related Signature with Prognostic Power in Gliomas

Identification and Validation of SNHG Gene Signature to Predict Malignant Behaviors and Therapeutic Responses in Glioblastoma

Identification and Analysis of Glioblastoma Biomarkers Based on Single Cell Sequencing

Single-cell Transcriptome-Based Multilayer Network Biomarker for Predicting Prognosis and Therapeutic Response of Gliomas

Prognostic Markers Identification in Glioma by Gene Expression Profile Analysis

Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates

Identification of Potential Biomarkers of Platelet RNA in Glioblastoma by Bioinformatics Analysis.

Identification and Validation of a 17-Gene Signature to Improve the Survival Prediction of Gliomas

Identification of Key Immune and Cell Cycle Modules and Prognostic Genes for Glioma Patients through Transcriptome Analysis

Prognosis Analysis and Validation of m6A Signature and Tumor Immune Microenvironment in Glioma

Bioinformatics Analysis and Experimental Validation for Exploring Key Molecular Markers for Glioblastoma

Predicting prognostic markers for glioma using gene co-expression network analysis.

m <sup>6</sup>A Signature and Tumour Immune Microenvironment for Predicting Prognostic Value in Gliomas

Candidate Biomarkers and Molecular Mechanism Investigation for Glioblastoma Multiforme Utilizing WGCNA.

Identification of Novel Lncrna Markers in Glioblastoma Multiforme and Their Clinical Significance: A Study Based on Multiple Sequencing Data

Integrated Analysis of ceRNA Network to Reveal Potential Prognostic Biomarkers for Glioblastoma

Integrated Analysis to Evaluate the Prognostic Value of Signature Mrnas in Glioblastoma Multiforme

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Identification of candidate biomarkers for GBM based on WGCNA

EPCO-24. MACHINE LEARNING ALGORITHMS UTILIZING TRANSCRIPTIONAL SIGNATURES PREDICT SURVIVAL OUTCOMES IN GLIOMA